D L Riddle1, P W Stratford2, R A Perera3. 1. Department of Physical Therapy, Virginia Commonwealth University, Richmond, VA, USA; Department of Orthopaedic Surgery, Virginia Commonwealth University, Richmond, VA, USA; Department of Rheumatology, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: dlriddle@vcu.edu. 2. School of Rehabilitation Science, Institute for Applied Sciences, McMaster University, Hamilton, Ontario, Canada. 3. Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.
Abstract
OBJECTIVES: No clinical prediction rules were found for estimating the likelihood of developing incident radiographic tibiofemoral osteoarthritis (OA) with rapid progression. Such a tool would enhance prognostic capability for clinicians and researchers. DESIGN: We used two longitudinal datasets to independently derive (Multicenter Osteoarthritis Study) and validate (Osteoarthritis Initiative) a prognostic clinical prediction rule for estimating the probability of incident rapidly progressing radiographic knee OA in the following 4-5 years. Eligible subjects had at least one knee with a Kellgren and Lawrence (K&L) graded tibiofemoral joint of 0 or 1. Several potential risk factors were examined including obesity, age, knee alignment, frequent knee symptoms, contralateral knee OA and knee injury history. Multiple logistic regression was used to identify significant predictors and area under the receiver operating characteristic curve (AUC) was used to assess discrimination. RESULTS: A total of 1690 subjects participated in the derivation and 2422 subjects participated in the validation of the clinical prediction rule. The multivariable model displayed good discrimination with AUC of 0.79 in the derivation dataset and 0.81 in the validation dataset. CONCLUSIONS: Persons with contralateral knee OA, a baseline index knee OA grade of 1, higher body mass index (BMI) and higher baseline Western Ontario and McMaster Universities arthritis index total scores were more likely to develop K&L grade of 3 or 4 within 5 years. Frequent knee symptoms at baseline were not a significant predictor. The prediction rule and nomogram can assist clinicians in estimating the probability of rapidly progressing radiographic knee OA and the nomogram can assist researchers conducting epidemiologic studies and clinical trials.
OBJECTIVES: No clinical prediction rules were found for estimating the likelihood of developing incident radiographic tibiofemoral osteoarthritis (OA) with rapid progression. Such a tool would enhance prognostic capability for clinicians and researchers. DESIGN: We used two longitudinal datasets to independently derive (Multicenter Osteoarthritis Study) and validate (Osteoarthritis Initiative) a prognostic clinical prediction rule for estimating the probability of incident rapidly progressing radiographic knee OA in the following 4-5 years. Eligible subjects had at least one knee with a Kellgren and Lawrence (K&L) graded tibiofemoral joint of 0 or 1. Several potential risk factors were examined including obesity, age, knee alignment, frequent knee symptoms, contralateral knee OA and knee injury history. Multiple logistic regression was used to identify significant predictors and area under the receiver operating characteristic curve (AUC) was used to assess discrimination. RESULTS: A total of 1690 subjects participated in the derivation and 2422 subjects participated in the validation of the clinical prediction rule. The multivariable model displayed good discrimination with AUC of 0.79 in the derivation dataset and 0.81 in the validation dataset. CONCLUSIONS:Persons with contralateral knee OA, a baseline index knee OA grade of 1, higher body mass index (BMI) and higher baseline Western Ontario and McMaster Universities arthritis index total scores were more likely to develop K&L grade of 3 or 4 within 5 years. Frequent knee symptoms at baseline were not a significant predictor. The prediction rule and nomogram can assist clinicians in estimating the probability of rapidly progressing radiographic knee OA and the nomogram can assist researchers conducting epidemiologic studies and clinical trials.
Authors: Manish Kothari; Ali Guermazi; Gabriele von Ingersleben; Yves Miaux; Martine Sieffert; Jon E Block; Randall Stevens; Charles G Peterfy Journal: Eur Radiol Date: 2004-05-19 Impact factor: 5.315
Authors: Weiya Zhang; Daniel F McWilliams; Sarah L Ingham; Sally A Doherty; Stella Muthuri; Kenneth R Muir; Michael Doherty Journal: Ann Rheum Dis Date: 2011-05-25 Impact factor: 19.103
Authors: Neil A Segal; Michael C Nevitt; K Douglas Gross; Keith D Gross; Jean Hietpas; Natalie A Glass; Cora E Lewis; James C Torner Journal: PM R Date: 2013-08 Impact factor: 2.298
Authors: L Sheehy; D Felson; Y Zhang; J Niu; Y-M Lam; N Segal; J Lynch; T D V Cooke Journal: Osteoarthritis Cartilage Date: 2010-10-13 Impact factor: 6.576
Authors: Julie Davis; Charles B Eaton; Grace H Lo; Bing Lu; Lori Lyn Price; Timothy E McAlindon; Mary F Barbe; Jeffrey B Driban Journal: Clin Rheumatol Date: 2017-02-10 Impact factor: 2.980
Authors: Cesar Garriga; Maria T Sánchez-Santos; Andrew Judge; Deborah Hart; Tim Spector; Cyrus Cooper; Nigel K Arden Journal: Arthritis Care Res (Hoboken) Date: 2020-01 Impact factor: 4.794
Authors: B Guan; F Liu; A Haj-Mirzaian; S Demehri; A Samsonov; T Neogi; A Guermazi; R Kijowski Journal: Osteoarthritis Cartilage Date: 2020-02-06 Impact factor: 6.576
Authors: Julie E Davis; Lori Lyn Price; Grace H Lo; Charles B Eaton; Timothy E McAlindon; Bing Lu; Mary F Barbe; Jeffrey B Driban Journal: Rheumatol Int Date: 2017-08-22 Impact factor: 2.631
Authors: Julie E Davis; Robert J Ward; James W MacKay; Bing Lu; Lori Lyn Price; Timothy E McAlindon; Charles B Eaton; Mary F Barbe; Grace H Lo; Matthew S Harkey; Jeffrey B Driban Journal: Rheumatology (Oxford) Date: 2019-03-01 Impact factor: 7.580
Authors: Jeffrey B Driban; Julie E Davis; Bing Lu; Lori Lyn Price; Robert J Ward; James W MacKay; Charles B Eaton; Grace H Lo; Mary F Barbe; Ming Zhang; Jincheng Pang; Alina C Stout; Matthew S Harkey; Timothy E McAlindon Journal: Arthritis Rheumatol Date: 2019-05-21 Impact factor: 10.995